Harbinger Health key facts
as of Oct 2026- Developer of an AI-enabled blood-based cancer detection platform designed to identify cancers in a pre-disease state and reduce cancer-related uncertainty for clinicians and patients.
- Harbinger Health is valued at approximately $520.0M as of Oct 2026 (last reported valuation).
- It has raised $290.0M; the latest was Later Stage VC ($100.0M) in Jan 2025.
- Notable investors include Partners Investment, Modi Ventures, Flagship Pioneering, Pictet, Catalyst Housing Group — 6 tracked in total.
- Status: Privately Held (backing).
Harbinger Health's last reported valuation, Sep 2023. Nothing priced has surfaced since.
- ·Watch Harbinger Health: the Monday email on marks, rounds and moves
Harbinger Health funding rounds
No funding rounds for Harbinger Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Harbinger Health
6Harbinger Health valuation
Harbinger Health's last reported valuation was $520 million in Sep 2023. No priced round, secondary trade or fund mark has surfaced since.
Harbinger Health investors
6 investors are on record for Harbinger Health, including Partners Investment, Modi Ventures, Flagship Pioneering and Pictet.
About Harbinger Health
Developer of an AI-enabled blood-based cancer detection platform designed to identify cancers in a pre-disease state and reduce cancer-related uncertainty for clinicians and patients. The company offers proprietary blood-based tests, AI-driven biological analysis, and advanced screening technologies, enabling underserved individuals facing healthcare disparities to access early, affordable cancer detection.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 65
- Website
- harbinger-health.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.